Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10909275 | Leukemia Research | 2012 | 7 Pages |
Abstract
Forty-eight patients received CPX-351 (liposome-encapsulated cytarabine:daunorubicin at a 5:1 molar ratio) every other day for 3 doses at 10 dose levels. Pharmacokinetic parameters were dose-independent and exhibited low inter-patient variability. CPX-351 showed a negligible distribution phase and prolonged mono-exponential first-order plasma elimination (t1/2 â¼Â 24 h). The plasma ratio of 5:1 was maintained at all dose levels. Nearly all of the detectable cytarabine and daunorubicin in circulation following CPX-351 administration was in the form of liposome encapsulated drug. Dose-dependent hematopoietic effects had early onset with cytopenias at 12 units/m2, and a gradual increase in frequency and severity, until single induction complete response was achieved at 43 units/m2. Non-hematologic effects had onset by 24 units/m2 with shallow dose-response until maximum frequency and severity were observed at the 101-134 units/m2 dose levels. Single induction response occurred over a 2.3-fold range of doses indicating that CPX-351 may be useful at high doses for patients suitable for intensive chemotherapy and at reduced doses for patients at increased risk of treatment-related mortality. The unique pharmacologic features of CPX-351 contribute to its promising antileukemic efficacy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
E.J. Feldman, J.E. Kolitz, J.M. Trang, B.D. Liboiron, C.E. Swenson, M.T. Chiarella, L.D. Mayer, A.C. Louie, J.E. Lancet,